Skip to main content

Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.

Publication ,  Journal Article
Bajorin, DF; Bosl, GJ; Alcock, NW; Niedzwiecki, D; Gallina, E; Shurgot, B
Published in: Cancer Res
November 1986

Nephrotoxicity, the dose-limiting toxicity of cis-diamminedichloroplatinum(II) (CDDP), is ameliorated when administered in hypertonic saline with normal saline hydration. To determine whether the diminished nephrotoxicity is associated with alteration of the pharmacokinetics of CDDP, we examined the pharmacokinetics of free and total platinum, platinum renal excretion, and urine electrolytes in patients given CDDP in hypertonic saline and in patients given CDDP in a conventional manner. The pharmacokinetics of free and total platinum for equal doses of CDDP were similar regardless of the vehicle of administration and the method of hydration. CDDP given in a vehicle of high chloride concentration with normal saline hydration resulted in a statistically significant increase in both urine volume and chloruresis compared to the conventional regimen. The decreased nephrotoxicity associated with administration of CDDP in hypertonic saline with saline diuresis may be related to increased chloruresis, urinary volume, or a combination of both, but did not appear to be related to an alteration in the pharmacokinetics.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

November 1986

Volume

46

Issue

11

Start / End Page

5969 / 5972

Location

United States

Related Subject Headings

  • Saline Solution, Hypertonic
  • Platinum
  • Pharmaceutical Vehicles
  • Oncology & Carcinogenesis
  • Middle Aged
  • Metabolic Clearance Rate
  • Humans
  • Cisplatin
  • Chlorides
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bajorin, D. F., Bosl, G. J., Alcock, N. W., Niedzwiecki, D., Gallina, E., & Shurgot, B. (1986). Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res, 46(11), 5969–5972.
Bajorin, D. F., G. J. Bosl, N. W. Alcock, D. Niedzwiecki, E. Gallina, and B. Shurgot. “Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.Cancer Res 46, no. 11 (November 1986): 5969–72.
Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res. 1986 Nov;46(11):5969–72.
Bajorin, D. F., et al. “Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.Cancer Res, vol. 46, no. 11, Nov. 1986, pp. 5969–72.
Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res. 1986 Nov;46(11):5969–5972.

Published In

Cancer Res

ISSN

0008-5472

Publication Date

November 1986

Volume

46

Issue

11

Start / End Page

5969 / 5972

Location

United States

Related Subject Headings

  • Saline Solution, Hypertonic
  • Platinum
  • Pharmaceutical Vehicles
  • Oncology & Carcinogenesis
  • Middle Aged
  • Metabolic Clearance Rate
  • Humans
  • Cisplatin
  • Chlorides
  • Aged